2004 Vol.22, N°5 - Suppl.35 - Table of contents
Title: Benefit/risk of new drugs for rheumatoid arthritis
Page 1
| Page | Article - [Author(s)] | Abs. | CME | Audio | Media | |
|---|---|---|---|---|---|---|
| Introduction | ||||||
| CER2363 2004,22,5,Suppl.35 Pg. 0001 | Introduction A. Kavanaugh, R.F. van Vollenhoven, T. Pincus › Free to View |  |  | |||
| Full Paper | ||||||
| CER2364 2004,22,5,Suppl.35 Pg. 0002-0011 | "Benefit/risk of therapies for rheumatoid arthritis: Underestimation of the ""side effects"" or risks of ra leads to underestimation of the benefit/risk of therapies" T. Pincus, A. Kavanaugh, T. Sokka › Free to View | | | |||
| CER2365 2004,22,5,Suppl.35 Pg. 0012-0017 | Undifferentiated arthritis - Disease course assessed in several inception cohorts K.N. Verpoort, H. van Dongen, C.F. Allaart, R.E.M. Toes, F.C. Breedveld, T.W.J. Huizinga › Free to View | | | |||
| CER2366 2004,22,5,Suppl.35 Pg. 0018-0025 | New approaches to imaging early inflammatory arthritis A.K. Brown, R.J. Wakefield, P.G. Conaghan, Z. Karim, P.J. O’Connor, P. Emery › Free to View | | | |||
| CER2367 2004,22,5,Suppl.35 Pg. 0026-0033 | Quantitative documentation of benefit/risk of new therapies for rheumatoid arthritis: Patient questionnaires as an optimal measure in standard care T. Pincus, T. Sokka, A. Kavanaugh › Free to View | | | |||
| CER2368 2004,22,5,Suppl.35 Pg. 0034-0038 | Internet-based monitoring of patients with rheumatoid arthritis S.J. Lee, L. Lenert, A. Kavanaugh › Free to View | | | |||
| CER2369 2004,22,5,Suppl.35 Pg. 0039-0043 | Mandatory pharmacosurveillance – A Canadian model for access to therapy and research S.G. Barr, L. Martin, C. Chung, W.P. Maksymowych › Free to View | | | |||
| CER2370 2004,22,5,Suppl.35 Pg. 0044-0049 | Healing of erosive changes in rheumatoid arthritis R. Rau, G. Herborn, S. Wassenberg › Free to View | | | |||
| CER2371 2004,22,5,Suppl.35 Pg. 0050-0056 | Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for near remission of DAS or single measures T. Pincus, T. Sokka, A. Kavanaugh › Free to View | | | |||
| CER2372 2004,22,5,Suppl.35 Pg. 0057-0064 | Longer term benefits of treating rheumatoid arthritis: Assessment of radiographic damage and physical function in clinical trials V. Strand › Free to View | | | |||
| CER2373 2004,22,5,Suppl.35 Pg. 0065-0070 | Cost-effectiveness of anti-tumor necrosis factor agents J.B. Wong › Free to View | | | |||
| CER2374 2004,22,5,Suppl.35 Pg. 0071-0076 | Benefit/risk of combination therapies D. Zerkak, M. Dougados › Free to View | | | |||
| CER2375 2004,22,5,Suppl.35 Pg. 0077-0082 | Glucocorticoid use in rheumatoid arthritis: Benefits, mechanisms, and risks H.B. Townsend, K.G. Saag › Free to View | | | |||
| CER2376 2004,22,5,Suppl.35 Pg. 0083-0094 | Benefit and risk of methotrexate treatment in rheumatoid arthritis R. Rau, G. Herborn › Free to View | | | |||
| CER2377 2004,22,5,Suppl.35 Pg. 0095-0100 | Benefit/risk of leflunomide in rheumatoid arthritis J.M. Kremer, G.W. Cannon › Free to View | | | |||
| CER2378 2004,22,5,Suppl.35 Pg. 0101-0107 | Benefit/risk of cyclosporine in rheumatoid arthritis E. Gremese, G.F. Ferraccioli › Free to View | | | |||
| CER2379 2004,22,5,Suppl.35 Pg. 0108-0114 | Overview of benefit/risk of biological agents A.K. Imperato, C.O. Bingham III, S.B. Abramson › Free to View | | | |||
| CER2380 2004,22,5,Suppl.35 Pg. 0115-0121 | Switching between biological agents R.F. van Vollenhoven › Free to View | | | |||
| CER2381 2004,22,5,Suppl.35 Pg. 0122-0125 | Benefits and risks of biological agents: Lymphomas R.F. van Vollenhoven › Free to View | | | |||
| CER2382 2004,22,5,Suppl.35 Pg. 0126-0133 | Tuberculosis and opportunistic infections: Relevance to biologic agents J. Bieber, A. Kavanaugh › Free to View | | | |||
| CER2383 2004,22,5,Suppl.35 Pg. 0134-0140 | Demyelination and inhibition of tumor necrosis factor (TNF) M.D. Magnano, W.H. Robinson, M.C. Genovese › Free to View | | | |||
| CER2384 2004,22,5,Suppl.35 Pg. 0141-0147 | Unusual toxicities with TNF inhibition: Heart failure and drug-induced lupus J.J. Cush › Free to View | | | |||
| CER2385 2004,22,5,Suppl.35 Pg. 0148-0150 | Safety issues related to emerging therapies for rheumatoid arthritis E.C. Keystone › Free to View | | | |||
Page 1
